Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IgPro20 in Primary Immunodeficiency
NCT07076446Phase 4Completed
- Sponsor
- CSL Limited
- Start
- Jul 2025
- Primary completion
- Jun 2026
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of IgPro20 in primary immunodeficiency (PI), sponsored by CSL Limited. Primary endpoints: Trough concentration at 13 weeks, Treatment-Emergent Adverse Events at 85 days and 2 more. Started Jul 2025; status: completed.
02
Drugs
IgPro20
03
Conditions
primary immunodeficiency (PI)
Beyond the preview
Go deeper on NCT07076446.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07076446.